Alnylam Pharmaceuticals ALNY Pre-Tax Income
Pre-Tax Income at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's pre-tax income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's pre-tax income?
- Alnylam Pharmaceuticals (ALNY) reported pre-tax income of $177.81M in Q2 2026.
- How has Alnylam Pharmaceuticals's pre-tax income changed year-over-year?
- Alnylam Pharmaceuticals's pre-tax income increased by 602.9% year-over-year, from -$35.36M to $177.81M.
- What is the long-term trend for Alnylam Pharmaceuticals's pre-tax income?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's pre-tax income has grown at a -23.8% compound annual growth rate (CAGR), from -$852.14M to $287.5M.
- What does pre-tax income mean?
- Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.